The syndemic effect of HIV/HCV co-infection and mental health disorders on acute care hospitalization rate among people living with HIV/AIDS: a population-based retrospective cohort study

Our primary objective was to examine the syndemic effect of HIV/HCV co-infection and mental health disorders (MHD) on the acute care hospitalization rate among people living with HIV (PLW-HIV) in British Columbia, Canada. Secondarily, we aimed to characterize the longitudinal trends in the aforementioned rate, while controlling for the effect of several factors. In this retrospective cohort study, individuals were antiretroviral therapy-naïve, ≥ 18 years old, initiated treatment between 1 January 2000 and 31 December 2014, and were followed for at least 6 months until 31 December 2015 or last contact. The outcome was acute care hospitalization rate (every 6-month interval) per individual. The exposure was the interaction between HIV/HCV co-infection and MHD. Generalized non-linear mixed-effects models were built. Of the 4046 individuals in the final analytical sample, 1597 (39%) were PLW-HIV without MHD, 606 (15%) were people living with HIV and HCV (PLW-HIV/HCV) without MHD, 988 (24%) were PLW-HIV with MHD, and 855 (21%) were PLW-HIV/HCV with MHD. The adjusted rate ratios for acute care hospitalizations were 1.31 (95% [confidence interval] 1.13–1.52), 2.01 (95% CI 1.71–2.36), and 2.53 (95% CI 2.20–2.92) for PLW-HIV with MHD, PLW-HIV/HCV without MHD, and PLW-HIV/HCV with MHD, respectively, relative to PLW-HIV without MHD. The HIV/HCV co-infection and MHD interaction demonstrated a significant effect on the rate of acute care hospitalization, particularly for PLW-HIV/HCV with MHD. Implementing widely accessible integrative care model best practices may address this public health challenge.

[1]  A. Reiss,et al.  Sex differences in psychiatric disorders: what we can learn from sex chromosome aneuploidies , 2018, Neuropsychopharmacology.

[2]  Casper W. Berg,et al.  glmmTMB Balances Speed and Flexibility Among Packages for Zero-inflated Generalized Linear Mixed Modeling , 2017, R J..

[3]  P. Harrigan,et al.  A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015 , 2017, Journal of the International AIDS Society.

[4]  M. Singer,et al.  Syndemics and the biosocial conception of health , 2017, The Lancet.

[5]  Z. Butt,et al.  The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC) , 2016, EBioMedicine.

[6]  C. Woods,et al.  Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease , 2016, Open forum infectious diseases.

[7]  P. Harrigan,et al.  Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes , 2015, AIDS.

[8]  J. Rockstroh,et al.  Natural history of liver disease and effect of hepatitis C virus on HIV disease progression , 2015, Current opinion in HIV and AIDS.

[9]  P. Tien,et al.  Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status. , 2015, AIDS patient care and STDs.

[10]  R. Hogg,et al.  The impact of scaling-up combination antiretroviral therapy on patterns of mortality among HIV-positive persons in British Columbia, Canada , 2015, Journal of the International AIDS Society.

[11]  R. Hogg,et al.  Cohort profile: Seek and treat for the optimal prevention of HIV/AIDS in British Columbia (STOP HIV/AIDS BC). , 2014, International journal of epidemiology.

[12]  S. Lewin,et al.  The end of AIDS: HIV infection as a chronic disease , 2013, The Lancet.

[13]  J. Walkup,et al.  Treatment Considerations for HIV-Infected Individuals with Severe Mental Illness , 2013, Current HIV/AIDS Reports.

[14]  L. Taylor,et al.  HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  P. Harrigan,et al.  Risk of Viral Failure Declines With Duration of Suppression on Highly Active Antiretroviral Therapy Irrespective of Adherence Level , 2010, Journal of acquired immune deficiency syndromes.

[16]  D. Vlahov,et al.  Prevention of HIV infection among injection drug users in resource-limited settings. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Spinelli,et al.  HCV co-infection in HIV positive population in British Columbia, Canada , 2010, BMC public health.

[18]  T. Patterson,et al.  The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART , 2007, AIDS.

[19]  W. Miller,et al.  Psychiatric Illness and Virologic Response in Patients Initiating Highly Active Antiretroviral Therapy , 2007, Journal of acquired immune deficiency syndromes.

[20]  D. Dieterich,et al.  Hepatitis C virus/human immunodeficiency virus coinfection: clinical management issues. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  S. Greenland,et al.  Simulation study of confounder-selection strategies. , 1993, American journal of epidemiology.

[22]  S. Gilbody,et al.  Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis , 2016, The lancet. Psychiatry.

[23]  P. Sammons,et al.  Mediation, Moderation & Interaction: Definitions, Discrimination & (Some) Means of Testing , 2013 .

[24]  T. Stockdale,et al.  Population estimates. , 2004, Health statistics quarterly.

[25]  Edwin D. Mares,et al.  On S , 1994, Stud Logica.

[26]  K. Fushimi,et al.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. , 2011, American journal of epidemiology.